Compounding and Mass-Tort Litigation: What Medical Practices Need to Know
Mass-tort litigation against compounding pharmacies and the practices that use them is a real and growing risk. Here is what the litigation landscape looks like and how to protect your practice.
Compounding and Mass-Tort Litigation: What Medical Practices Need to Know
The 2012 New England Compounding Center (NECC) meningitis outbreak — which killed 64 people and injured hundreds more — was the most devastating compounding-related mass-tort event in U.S. history. It led to the DQSA, transformed the regulatory landscape, and generated billions of dollars in litigation.
That event was an extreme case, but it illustrates a fundamental truth: compounding-related litigation is real, it can be catastrophic, and it can reach the prescribing practice, not just the compounder.
Our founding team includes mass-tort attorneys who have litigated pharmaceutical cases for 15+ years. Here is what we know about the litigation landscape and how to protect your practice.
The Litigation Landscape for Compounding
Types of Compounding-Related Litigation
Product liability claims: Patients who are harmed by a defective compounded product can bring product liability claims against the compounder and potentially against the prescribing practice.
Medical malpractice claims: Prescribers can face malpractice claims if they prescribed a compounded product without adequate clinical justification, failed to monitor the patient, or failed to recognize and respond to adverse events.
Regulatory enforcement: State medical boards and the FDA can take action against prescribers who are found to have violated prescribing standards.
Class actions: When a compounding pharmacy produces a contaminated or subpotent product that affects multiple patients, class action litigation can follow.
Recent Litigation Trends
GLP-1 compounding litigation: As the compounded GLP-1 market has grown, so has litigation. Cases have involved:
- Contaminated or subpotent compounded GLP-1 products
- Adverse events in patients who were not adequately screened or monitored
- Marketing claims that were not supported by evidence
Telehealth prescribing litigation: Telehealth platforms that prescribed GLP-1s without adequate patient evaluation have faced both regulatory action and civil litigation.
Supply chain liability: Practices that sourced from non-compliant compounders have faced liability when patients were harmed.
How Liability Reaches the Prescribing Practice
Many prescribers assume that if a patient is harmed by a compounded product, the liability rests with the compounder. This assumption is wrong.
Negligent selection of supplier: If a prescriber selects a compounding supplier without conducting appropriate due diligence, and a patient is harmed by a product from that supplier, the prescriber can face liability for negligent selection.
Failure to monitor: If a prescriber prescribes a compounded product and fails to monitor the patient for adverse effects, and the patient is harmed, the prescriber faces malpractice exposure.
Inadequate informed consent: If a patient is not adequately counseled about the risks of compounded medications (including the fact that they are not FDA-approved), and the patient is harmed, the prescriber faces liability.
Prescribing outside standard of care: If a prescriber prescribes a compounded product in a manner that deviates from the standard of care, they face malpractice exposure regardless of whether the product itself was defective.
The Documentation Defense
The most important protection against compounding-related litigation is documentation. In any litigation, the question will be: what did the prescriber know, when did they know it, and what did they do about it?
Documentation that protects you includes:
Supplier due diligence: Document that you verified your supplier's licenses, reviewed their COA process, and checked for warning letters. This demonstrates that you exercised reasonable care in selecting your supplier.
Clinical rationale: Document why you prescribed a compounded product rather than a commercially available alternative. This is particularly important for GLP-1 compounds where branded alternatives exist.
Informed consent: Document that you counseled the patient about the risks and benefits of compounded medications, including the fact that they are not FDA-approved.
Monitoring: Document your monitoring of the patient's response to therapy and any adverse events.
Adverse event response: If a patient experiences an adverse event, document your assessment and response.
The Legal Background Advantage
At MedClinic Partners, our founding team includes mass-tort attorneys who have litigated against pharmaceutical companies for 15+ years. We have seen what happens when practices cut compliance corners — and we built this supply infrastructure specifically to help practices avoid those outcomes.
We are not just a supply partner — we are a compliance partner. We track regulatory changes, advise our clients proactively, and help them build the documentation infrastructure that protects them in litigation.
Contact us to discuss your compliance posture →
This content is for informational purposes only and does not constitute legal advice. Consult with qualified legal counsel regarding your specific liability exposure.
Explore Topics
Written by
MedClinic Partners Editorial Team
B2B Medical Supply & Compounding Experts
The MedClinic Partners editorial team is composed of licensed medical operators, compounding compliance specialists, and mass-tort attorneys with direct experience running GLP-1 and peptide programs across all 50 states. Every article is reviewed for clinical accuracy, regulatory compliance, and practical applicability before publication.
Editorial standards: All content on medclinicpartners.com is reviewed by licensed medical operators and compounding compliance specialists before publication. Articles are updated when regulatory guidance changes. This content is for licensed healthcare providers only and does not constitute medical advice.
